Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up

Eichenauer, Dennis;André, Marc;Borchmann, Peter;Collins, Graham;Aurer, Igor;et.al.
(2026) HemaSphere — Vol. 10, n° 6, p. e70422 (2026)

Files

Eichenauer DA, Hemasphere, 2026.pdf
  • Open Access
  • Adobe PDF
  • 642.48 KB
Download

Details

Authors
  • Eichenauer, Dennisorcid-logoFirst Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, German Hodgkin Study Group University of Cologne Cologne Germany
    Author
  • André, MarcUCLouvain
    Author
  • Borchmann, PeterFirst Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, German Hodgkin Study Group University of Cologne Cologne Germany
    Author
  • Collins, GrahamDepartment of Haematology, Oxford Cancer and Haematology Centre Churchill Hospital Oxford UK
    Author
  • Aurer, IgorUniversity Hospital Centre Zagreb and School of Medicine University of Zagreb Zagreb Croatia
    Author
  • et. al.
Show more
Abstract
Hodgkin lymphoma (HL) is a B-cell-derived malignancy often affecting young adults. Allocation into risk groups is based on staging with positron emission tomography and computed tomography (PET/CT) and the presence or absence of risk factors. Standard treatment for early-stage favorable classic HL (cHL) consists of two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), followed by 20 Gy involved-site radiotherapy (IS-RT). Two cycles of escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP) or a procarbazine-free eBEACOPP variant plus two cycles of ABVD, followed by 30 Gy IS-RT in the case of PET/CT positivity and no further treatment in the case of PET/CT negativity after chemotherapy should be considered in patients with early-stage unfavorable cHL ≤ 60 years. If a less intensive approach is preferred and in individuals > 60 years, four cycles of A(B)VD followed by 30 Gy IS-RT can be given. In advanced cHL, brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD) for four (in the case of PET/CT negativity after two cycles) or six cycles (in the case of PET/CT positivity after two cycles), followed by PET/CT-guided 30 Gy IS-RT should be considered in patients ≤ 60 years. Six cycles of nivolumab and AVD (N-AVD) followed by PET/CT-guided 30 Gy IS-RT represents a less intensive alternative for younger patients and the preferred approach for patients > 60 years. Patients with cHL recurrence should receive checkpoint inhibitor-containing salvage treatment followed by high-dose chemotherapy and autologous stem cell transplantation if eligible. Treatment of nodular lymphocyte-predominant HL differs from cHL in some situations and may contain an anti-CD20 antibody. This guideline aims at providing recommendations for diagnosis, staging, treatment, and follow-up of HL.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Eichenauer, D., André, M., Borchmann, P., Collins, G., Doherty, I., Eich, H.-t., Federico, M., Fossa, A., Hartmann, S., Hutchings, M., Illidge, T., Kobe, C., Plattel, W., Specht, L., Sureda, A., Zaucha, J., Zijlstra, J., Aurer, I., & et al. (2026). Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up. HemaSphere, 10(6), e70422. https://doi.org/10.1002/hem3.70422 (Original work published 2026)